Display options
Cite
Zucal I, Geis S, Prantl L, et al. Indocyanine Green for Leakage Control in Isolated Limb Perfusion. J Pers Med. 2021;11(11)doi: 10.3390/jpm11111152.
Zucal, I., Geis, S., Prantl, L., Haerteis, S., & Aung, T. (2021). Indocyanine Green for Leakage Control in Isolated Limb Perfusion. Journal of personalized medicine, 11(11), . https://doi.org/10.3390/jpm11111152
Zucal, Isabel, et al. "Indocyanine Green for Leakage Control in Isolated Limb Perfusion." Journal of personalized medicine vol. 11,11 (2021). doi: https://doi.org/10.3390/jpm11111152
Zucal I, Geis S, Prantl L, Haerteis S, Aung T. Indocyanine Green for Leakage Control in Isolated Limb Perfusion. J Pers Med. 2021 Nov 05;11(11). doi: 10.3390/jpm11111152. PMID: 34834504; PMCID: PMC8619565.
Copy Download .nbib Format: NLM
Share it on

J Pers Med. 2021 Nov 05;11(11). doi: 10.3390/jpm11111152.

Indocyanine Green for Leakage Control in Isolated Limb Perfusion.

Journal of personalized medicine

Isabel Zucal, Sebastian Geis, Lukas Prantl, Silke Haerteis, Thiha Aung

Affiliations

  1. Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery, University Clinic of Regensburg, 93053 Regensburg, Germany.
  2. Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany.
  3. Faculty of Applied Healthcare Science, Deggendorf Institute of Technology, 94469 Deggendorf, Germany.

PMID: 34834504 PMCID: PMC8619565 DOI: 10.3390/jpm11111152

Abstract

Sarcomas are characterized by a high metastatic potential and aggressive growth. Despite surgery, chemotherapy plays an important role in the treatment of these tumors. Optimal anti-cancer therapy with maximized local efficacy and minimized systemic side effects has been the object of many studies for a long time. To improve the local efficacy of anti-tumor therapy, isolated limb perfusion with high-dose cytostatic agents has been introduced in surgical oncology. In order to control the local distribution of substances, radiolabeled cytostatic drugs or perfusion solutions have been applied but often require the presence of specialized personnel and result in a certain exposure to radiation. In this study, we present a novel strategy using indocyanine green to track tumor perfusion with high-dose cytostatic therapy. In a rat cadaver model, the femoral vessels were cannulated and connected to a peristaltic pump to provide circulation within the selected limb. The perfusion solution contained indocyanine green and high-dose doxorubicin. An infrared camera enabled the visualization of indocyanine green during limb perfusion, and subsequent leakage control was successfully performed. Histologic analysis of sections derived proximally from the injection site excluded systemic drug dispersion. In this study, the application of indocyanine green was proven to be a safe and cost- and time-efficient method for precise leakage control in isolated limb perfusion with a high-dose cytostatic agent.

Keywords: cytostatic agents; doxorubicin; indocyanine green; oncology; perfusion; surgical oncology

References

  1. Cancer. 2019 Mar 1;125(5):807-817 - PubMed
  2. Clin Physiol Funct Imaging. 2015 Jul;35(4):301-5 - PubMed
  3. Cancer. 2011 Jul 15;117(14):3235-41 - PubMed
  4. J Craniomaxillofac Surg. 2019 Nov;47(11):1819-1826 - PubMed
  5. Cancer Biol Med. 2016 Sep;13(3):373-383 - PubMed
  6. Ann Surg Oncol. 2014 Apr;21(4):1202-8 - PubMed
  7. Am J Med Sci. 2011 Jul;342(1):50-3 - PubMed
  8. Semin Oncol. 2007 Dec;34(6):498-508 - PubMed
  9. Plast Reconstr Surg Glob Open. 2020 Jul 23;8(7):e2912 - PubMed
  10. Sarcoma. 2011;2011:289673 - PubMed
  11. Ann Surg Oncol. 2007 Feb;14(2):568-76 - PubMed
  12. J Pak Med Assoc. 2014 Dec;64(12 Suppl 2):S139-43 - PubMed
  13. Cancer Manag Res. 2018 May 10;10:1089-1114 - PubMed
  14. J Reconstr Microsurg. 2011 Jul;27(6):355-64 - PubMed
  15. J Heart Lung Transplant. 2006 Apr;25(4):454-60 - PubMed
  16. Lancet Oncol. 2013 May;14(6):500-15 - PubMed
  17. Med Confl Surviv. 1999 Jan-Mar;15(1):57-70 - PubMed
  18. Int J Biomed Imaging. 2012;2012:940585 - PubMed
  19. J Surg Oncol. 2009 Aug 1;100(2):169-77 - PubMed
  20. J Hand Microsurg. 2013 Jun;5(1):14-7 - PubMed
  21. Gland Surg. 2020 Apr;9(2):596-602 - PubMed
  22. J Plast Reconstr Aesthet Surg. 2017 Jun;70(6):814-827 - PubMed
  23. Jpn J Clin Oncol. 2018 Dec 1;48(12):1036-1040 - PubMed
  24. Ann Surg Oncol. 2019 Mar;26(3):894-898 - PubMed
  25. Z Orthop Ihre Grenzgeb. 1992 May-Jun;130(3):197-201 - PubMed
  26. Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10 - PubMed
  27. Oncol Lett. 2014 May;7(5):1352-1362 - PubMed
  28. Surg Clin North Am. 2008 Jun;88(3):629-46, viii - PubMed
  29. Nat Rev Clin Oncol. 2013 Sep;10(9):507-18 - PubMed
  30. Microsurgery. 2017 Nov;37(8):947-953 - PubMed
  31. Surgery. 1963 Dec;54:900-11 - PubMed
  32. Int J Hyperthermia. 2016;32(2):165-72 - PubMed
  33. Surg Innov. 2016 Apr;23(2):166-75 - PubMed
  34. Oncologist. 2010;15(4):416-27 - PubMed
  35. J Am Coll Surg. 2013 Mar;216(3):380-9; quiz 511-3 - PubMed
  36. Nuklearmedizin. 1994 Dec;33(6):248-53 - PubMed
  37. Mayo Clin Proc. 2007 Nov;82(11):1409-32 - PubMed
  38. Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 - PubMed
  39. Z Orthop Ihre Grenzgeb. 1993 Sep-Oct;131(5):452-60 - PubMed
  40. J Transl Int Med. 2016 Apr 1;4(1):52-54 - PubMed
  41. Cancer Treat Rev. 2020 Aug;88:102058 - PubMed
  42. Clinics (Sao Paulo). 2012;67(3):237-41 - PubMed
  43. Biomedicines. 2021 Feb 07;9(2): - PubMed
  44. Nat Rev Cancer. 2010 Jun;10(6):425-34 - PubMed
  45. Indian J Orthop. 2018 Jan-Feb;52(1):35-44 - PubMed
  46. Tumori. 2001 May-Jun;87(3):187-90 - PubMed
  47. Front Surg. 2019 Jul 02;6:39 - PubMed
  48. J Surg Oncol. 2011 Sep 1;104(3):323-32 - PubMed
  49. Ann Surg Oncol. 2006 Aug;13(8):1123-9 - PubMed

Publication Types